CD39 and CD73 in immunity and inflammation
By Luca Antonioli, P. Pacher, E. Vizi, G. Haskó. Trends in Molecular Medicine, 2013
1,162 citations recorded by the source corpus.
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ecto-enzymes are novel therapeutic targets for managing a variety of disorders.
Subfields: Cardiology and Cardiovascular Medicine, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/fe19c3a22d3810c619094d97bce8f0121e3eb491
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Alexey I. Nesvizhskii
- Andy T. Kong
- David J. Clark
- Dmitry Avtonomov
- S. Dhanasekaran
- C. Ricketts
- F. Petralia
- A. Hakimi
Citations in the corpus
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2019, background): “Immune-based subtyping of ccRCC tumors via deconvolution of cell composition identified TME and cellular pathways that delineated patients who displayed a pro-angiogenic phenotype from those with an immune-evasive phenotype.”
- Drug resistance and combating drug resistance in cancer (2019, background): “ATP released from these immune cells as well as dying or stressed cells can be sequentially converted to AMP and adenosine by cell surface enzymes CD39 (ecto-nucleoside triphosphate diphosphohydrolase 1, E-NTPDase1) and CD73 (ecto-5’-nucleotidase, Ecto5’NTase)([195,196]).”